查詢結果分析
相關文獻
- Albumin Administration in Patients with Severe Sepsis Due to Secondary Peritonitis
- 不同尿酸濃度對慢性血液透析病人之長期預後影響
- 蛋白質流失腸病變及其處置用藥介紹
- 小腸淋巴管擴張症病人之營養照顧
- RIFLE Classification Did Not Have Satisfactory Predictive Value for Septic Patients with High Severity Scores
- Hypoalbuminemia Is Better than Hypocholesterolemia for Prognostic Prediction in Pyogenic Liver Abscess
- Serum Albumin is the Important Determinant of Mortality in Mechanically Ventilated Critically Ill Patients
- Recombinant Human Activated Protein C Reduces Mortality of Severe Sepsis-Related ARDS
- 重症急性腎損傷病人之營養評估與介入
- 低白蛋白血症
頁籤選單縮合
| 題 名 | Albumin Administration in Patients with Severe Sepsis Due to Secondary Peritonitis=白蛋白注射對於續發性腹膜炎合併嚴重敗血症病人的療效評估 |
|---|---|
| 作 者 | 周志道; 尹彙文; 吳德敏; 郭正典; | 書刊名 | Journal of the Chinese Medical Association |
| 卷 期 | 72:5 2009.05[民98.05] |
| 頁 次 | 頁243-250+CA46 |
| 分類號 | 415.57 |
| 關鍵詞 | 白蛋白; 低白蛋白血症; 死亡率; 續發性腹膜炎; 嚴重敗血症; Albumin; Hypoalbuminemia; Mortality; Secondary peritonitis; Severe sepsis; |
| 語 文 | 英文(English) |
| 英文摘要 | Background: To determine whether or not intravenous administration of human albumin can reduce mortality in patients with severe sepsis due to secondary peritonitis. Methods: Adult patients who were admitted to the surgical intensive care unit (SICU) who fulfilled the criteria of severe sepsis due to secondary peritonitis were consecutively included in this retrospective study. Patients who received and those who did not receive at least a daily minimum of 25 g intravenous human albumin for 3 days during their first 7 days of SICU admission were classified as the study group and control group, respectively. Results: A total of 133 patients were included in this study. For patients with baseline serum albumin ≤ 20 g/L, 28-day mortality was significantly lower in the study group. For patients with baseline serum albumin > 20 g/L, albumin administration had no significant effects on 28-day mortality. Conclusion: For patients with severe sepsis due to secondary peritonitis, albumin administration may reduce 28-day mortality in patients whose baseline serum albumin is ≤ 20 g/L, but no such effect was found in patients whose baseline serum albumin was > 20 g/L. |
本系統中英文摘要資訊取自各篇刊載內容。